OmniAb Reports Q3 2026 Revenue Growth and Raises Full-Year Guidance
OmniAb (OABI) reported third-quarter revenue of $4 million, a significant increase from $2.2 million in the prior year period. This growth was primarily driven by service and xPloration platform revenues. Following strong milestone achievements, management raised its full-year 2026 revenue guidance to a range of $35 million to $39 million. The company's strategic collaboration with Eli Lilly remains a major driver, offering potential research, development, and commercial payments totaling $370 million for a novel ion channel program. OmniAb currently manages 433 active programs and maintains partnerships with nine of the world's ten largest pharmaceutical companies. Despite a net loss of $15.7 million for the quarter, the company improved its cash position to $64.2 million.
Topics: Cash Flow Guidance Raise Net Loss Partnerships Revenue Growth